期刊文献+

DLC1基因对人卵巢癌细胞OVCAR-3顺铂耐药性的影响 被引量:1

The effect of DLC1 gene on chemoresistance in human ovarian cancer cell line OVCAR-3
下载PDF
导出
摘要 背景与目的:有研究发现,肝癌缺失基因1(DLC1)在多种肿瘤中低表达或不表达,其通过调节黏着斑激酶(FAK)、促分裂原活化蛋白激酶(MAPK)等影响肿瘤细胞的凋亡。而对于DLC1在卵巢癌中的表达及作用等的研究甚少,本实验采用DLC1基因转染该基因表达缺失的人卵巢癌多药耐药细胞系OVCAR-3,观察转染前后该细胞对顺铂耐药性及FAK、p38MAPK的变化。方法:将OVCAR-3细胞分为3组,空白组为未经处理的OVCAR-3细胞,阴性对照组转染空质粒pEGFP-C3,实验组转染重组质粒pEGFP-C3-DLC1。RT-PCR和Western blot检测各组细胞中DLC1基因和蛋白的表达,四甲基偶氮唑蓝(MTT)法测定各组细胞对顺铂的半数抑制浓度(IC50),Western blot观察FAK、p38蛋白及其磷酸化水平的变化,流式细胞仪测定顺铂处理前后各组细胞凋亡率及周期分布改变。结果:DLC1基因和蛋白在实验组表达而空白对照组和阴性对照组均未见表达,实验组细胞与其他两组细胞相比,对顺铂的IC50较低(4.02 vs 4.99/4.90μmol/L,P<0.01),p-p38蛋白表达上升而p-FAK蛋白表达下降(3.02 vs 1.52/1.61,3.13 vs 9.03/8.99,P<0.01),顺铂处理前后实验组与其他两组细胞相比凋亡率增加(8.97%vs 1.81%/1.95%,30.68%vs 18.03%/20.33%,P<0.01),G1期细胞比例增加(65.80%vs 60.82%/59.80%,66.48%vs 55.42%/53.94%,P<0.05)。结论:转染DLC1基因可使OVCAR-3G1期细胞比例及凋亡率升高,对顺铂敏感性增加,该作用可能依赖于细胞内外源性DLC1基因的表达、p-FAK表达降低和p-p38表达增强。 Background and purpose:The deleted in liver cancer gene1(DLC1) is lowly or negatively expressed in different cancers and have an effect on the apoptosis of cancer cells due to the regulation of focal adhesion kinase(FAK) and mitogen-actived protein kinase(MAPK).However,the expression level and role of the DLC1 gene in ovarian cancer has been rarely studied.This study aimed to transfect the DLC1 gene into the OVCAR-3 cells,where the DLC1 gene was once negatively expressed,so as to investigate the effect of the DLC1 gene on chemoresistance as well as a variation of FAK and p38MAPK.Methods:Ovarian cancer cell line OVCAR-3 was treated with none(blank group),empty plasmid pEGFP-C3(negative control group) and pEGFP-C3-DLC1(experimental group).The expression of DLC1 mRNA and protein were detected separately using RT-PCR and Western blot.The IC50 of cisplatin was determined using the Methyl thiazolyl tetrazolium test(MTT).The changes of FAK and p38 protein expression and their phosphorylated status were determined by Western blot.Apoptosis and cell cycle distribution were detected by flow cytometry.Results:DLC1 gene and protein were only observed in the experiment group rather than in the other groups.The IC50 of the experiment group was lower than in the other groups(4.02 vs 4.99/4.90 μmol/L,P〈0.01).There was a higher expression of p-p38 but lower expression of p-FAK(3.02 vs 1.52/1.61,3.13 vs 9.03/8.99,P〈0.01) after the treatment of cisplatin in experimental group.Apoptosis was significantly higher and G1 arrest was oberved only in the experimental group after the treatment of cisplatin,there were statistically differences among the groups(P〈0.01).Conclusion:The OVCAR-3 cells were more sensitive to cisplatin after transient transfection of DLC1 gene in terms of the induction of apoptosis and G1 arrest,which might be through the upregulation of p-FAK expression and downregulation of p-p38 expression.
出处 《中国癌症杂志》 CAS CSCD 北大核心 2011年第2期103-109,共7页 China Oncology
基金 河南省医学科技攻关计划重大项目(No:20090113)
关键词 DLC1基因 卵巢癌 逆转耐药 凋亡 细胞周期 DLC1 gene Ovarian cancer Reverse chemoresistance Apoptosis Cell cycle
  • 引文网络
  • 相关文献

参考文献14

  • 1Huang C, Jacobson K, Schaller MD. MAP kinases and cell migration [ J ] . Cell Sci. 2004. 117: 4619-4628.
  • 2Sliver DL, Naora H, Liu J, et al. Activated signal transducer and function in ovarian cancer cell motility [ J ] . Cancer Res. 2004, 64: 3550-3558.
  • 3Kim TY, Lee JW, Kim HP. el al. DLC-1. a GTPase- activating protein for Rho, is associated with cell prnliferatifm, morphology, and migration in human hepatocellular carcinoma [ J ]. Biochem Biophys Res Commun, 2007. 355(1 ): 72-77.
  • 4Olivero M, Ruggiero T. Saviozzi S. et al. Gene regulated by hepatocyte growth factor as targets to sensitize ovarian cancer cells to cisplatin [ J ] . Mol Cancer Ther. 2006. 5(5): 1126- 1135.
  • 5何卫华,史惠蓉.卵巢上皮性癌组织中黏着斑激酶和肝癌缺失基因-1 mRNA的表达[J].郑州大学学报(医学版),2010,45(2):209-213. 被引量:3
  • 6Die/mar P, Peter H, Andreas G, et al. Five genes from band 8p22 are significantly down-regulated in ovarian carcinoma [ J ] . Cancer, 2005, 104(11): 2417-2429.
  • 7Zhou XL, Thorgeirsson SS, Popescu NC. Restoration of DLC- 1 gene expression induces apoptosis and inhibits both cell growth and tumorigenieity in human hepatocellular carcinonm ceils [ J ] . Oncogene, 2004, 23: 1308-1313.
  • 8戴宏宇,刘琳,何向明,李苏宜,秦叔逵.洛铂体外诱导人结肠癌细胞株LOVO细胞凋亡及其作用机制的研究[J].中国癌症杂志,2010,20(11):837-841. 被引量:6
  • 9Ko FC, Yeung YS, Wong CM. et al. Deleted in liver cancer 1 isoforms are distinctly expressed in human tissues, functionally different and under differential transcriptional regulation in hepatocellular carcinoma [ J ] . Liver Int, 2010, 30(1): 139- 148.
  • 10Yuan BZ, Miller M J, Keck CL, et al. Cloning, characterization, and chromosomal localization of a gene frequently delete in human liver cancer(DLC-1) homologous to rat RhoGAP [ J ] . Cancer Res, 1998, 58: 2196-2199.

二级参考文献36

  • 1栾英姿,李力,黎丹戎,张玮,唐步坚.五种卵巢癌耐药细胞系的建立及其部分耐药相关基因的表达[J].中华妇产科杂志,2004,39(6):403-407. 被引量:21
  • 2陈文勇,陈映.化学发光在核酸探针诊断中的应用及其进展[J].国外医学(临床生物化学与检验学分册),1993,14(2):51-53. 被引量:3
  • 3张晓菁,姚晓奕,常玉华,贾艳敏.卵巢癌耐药细胞株体外模型的建立及相关研究[J].山东医药,2005,45(32):3-5. 被引量:2
  • 4Golubovskaya VM, Kweh FA, Cance WG. Focal adhesion kinase and cancer [ J ]. Histol Histopathol, 2009,24 ( 4 ) : 503.
  • 5Liao YC, Lo SH. Deleted in liver cancer-1 (DLC-1) : a tumor suppressor not just for liver[J]. Int J Biochem Cell Biol, 2008,40(5):843.
  • 6Kim TY, Lee JW, Kim HP, et al. DLC-1, a GTPase-aetivating protein for Rho, is associated with cell proliferation, morphology, and migration in human hepatocellular carcinoma[ J]. Biochem Biophys Res Commun,2007, 355 ( 1 ) : 72.
  • 7Zhao J, Guan JL. Signal transduction by focal adhesion kinase in cancer [ J ]. Cancer Metastasis Rev, 2009,28 ( 1/ 2) :35.
  • 8Chatzizacharias NA, Kouraklis GP, Theoeharis SE. Clinical significance of FAK expression in human neoplasia [ J]. Histol Histopathol,2008,23(5) :629.
  • 9Fujii T, Koshikawa K, Nomoto S, et al. Focal adhesion kinase is overexpressed in hepatocellular carcinoma and can be served as an independent prognostic factor[ J]. J Hepatol,2004,41 ( 1 ) :104.
  • 10de Heer P,Koudijs MM,van de Velde CJ,et al. Combined expression of the non-receptor protein tyrosine kinases FAK and Src in primary colorectal cancer is associated with tumor recurrence and metastasis formation[J]. Eur J Surg Oncol,2008,34( 11 ) :1 253.

共引文献10

同被引文献15

  • 1JEMAL A, BRAY F,CENTER M M, et al. Global cancerstatistics [J]. CA Cancer J Clin, 2011, 61(2): 69-90.
  • 2HE Q, ZHANG G, HOU D, et al. Overexpression of sorcinresults in multidrug resistance in gastric cancer cells with up-regulation of P-gp[J]. Oncol Rep, 2011, 25(1): 237-243.
  • 3ZHENG B B, ZHANG P, JIA W W, et al. Sorcin, a potentialtherapeutic target for reversing multidrug resistance in cancer[J]. J Physiol Biochem, 2012, 68(2): 281-287.
  • 4DENG L, SU T, LENG A, et al. Upregulation of solubleresistance-related calcium-binding protein (sorcin) in gastriccancer [J]. Med Oncol, 2010,27(4): 1102-1108.
  • 5HE Q, ZHANG G, HOU D, et al. Overexpression of sorcinresults in multidrug resistance in gastric cancer cells with up-regulation of p-gp [J]. Oncol Rep, 2011, 25(1): 237-243.
  • 6MADDALENA F,LAUDIERO G,PISCAZZI A, et al. Sorrininduces a drug-resistant phenotype in human colorectalcancer by modulating Ca(2+) homeostasis [J]. Cancer Res,2011,71(24): 7659-7669.
  • 7QU Y, YANG Y, LIU B, et al. Comparative proteomic profilingidentified sorcin being associated with gemcitabine resistancein non-small cell lung cancer [J]. Med Oncol, 2010, 27(4):1303-1308.
  • 8TAN Y, LI G, ZHAO C, et al. Expression of sorcin preriictspoor outcome in acute myeloid leukemia [J], Leuk Res, 2003,27(2): 125-131.
  • 9KAWAKAMI M,NAKAMURA T, OKAMURA N, et al.Knock-down of sorcin induces up-regulation of mdrl in helacells [J]. Biol Pharm Bull, 2007, 30(6): 1065-1073.
  • 10SUAREZ J, MCDONOUGH P M, SCOTT B T, et al. Sorcinmodulates mitochondrial Ca2+ handling and reduces apoptosisin neonatal rat cardiac myocytes [J]. Am J Physiol Cell Physiol,2013,304(3): 248-256.

引证文献1

二级引证文献3

;
使用帮助 返回顶部